These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 452427)
1. [Effect of chemotherapy on the survival of patients with generalized plasmacytoma and various hazards of its toxicity]. Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J; Oravská D; Pokorná G; Mayer J Vnitr Lek; 1979 May; 25(5):425-35. PubMed ID: 452427 [No Abstract] [Full Text] [Related]
2. [Duration of disease and survival time in plasmacytoma]. Rautenstrauch H Z Gesamte Inn Med; 1970 Dec; 25(23):1071-4. PubMed ID: 5512749 [No Abstract] [Full Text] [Related]
3. [Clinical trial with long-term therapy of generalized plasmacytoma]. Sakalová A; Gazová S; Makaiová I Folia Haematol Int Mag Klin Morphol Blutforsch; 1977; 104(1):57-63. PubMed ID: 69574 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501 [TBL] [Abstract][Full Text] [Related]
6. Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model. Ghanta VK; Cohen HJ; Silberman HR; Durant JR; Hiramoto RN Cancer Clin Trials; 1981; 4(2):135-41. PubMed ID: 7249251 [TBL] [Abstract][Full Text] [Related]
7. [Cytostatic treatment of plasmacytoma]. Günther I; Gladitz G Z Gesamte Inn Med; 1972 Nov; 27(21):933-7. PubMed ID: 4662918 [No Abstract] [Full Text] [Related]
8. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone. Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771 [TBL] [Abstract][Full Text] [Related]
9. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy]. Korolenko VO; Gershanovich ML; Tikhonova VV Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764 [No Abstract] [Full Text] [Related]
10. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Kalinka-Warzocha E; Wajs J; Lech-Maranda E; Ceglarek B; Holowiecki J; Federowicz I; Walewski J; Czyz J; Robak T; Warzocha K; Cancer; 2008 Jul; 113(2):367-75. PubMed ID: 18470902 [TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560 [TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285 [TBL] [Abstract][Full Text] [Related]
14. Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations. Smalley RV; Bartolucci AA Eur J Cancer (1965); 1980; Suppl 1():141-6. PubMed ID: 7318861 [No Abstract] [Full Text] [Related]
15. Combination chemotherapy in Hodgkin's disease. Nordentoft AM; Jensen KB Dan Med Bull; 1973 Mar; 20(2):52-60. PubMed ID: 4688460 [No Abstract] [Full Text] [Related]
16. [Multiple drug therapy in Hodgkin's disease, lymphosarcoma and reticulosarcoma]. Con I; Daiber A; Donoso A; Osorio G; Mora F Rev Med Chil; 1972 Apr; 100(4):408-13. PubMed ID: 4557485 [No Abstract] [Full Text] [Related]
17. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
18. [Life expectancy of hemoblastosis patients]. Obrecht P Med Klin; 1966 Dec; 61(50):1985-90. PubMed ID: 5239386 [No Abstract] [Full Text] [Related]
19. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage]. Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383 [TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy for disseminated carcinoma of the breast. Lozada JA; Grillo-López A; Vélez-Garciá E Bol Asoc Med P R; 1975 Jun; 67(6):157-63. PubMed ID: 1055588 [No Abstract] [Full Text] [Related] [Next] [New Search]